Payment overview · 2025
General Payments
$525.76
25 reported records · 11 companies
Healthcare provider profile · identity verified
Thomas R Mann, M.D.PC
Allopathic & Osteopathic Physicians|Internal Medicine · FITZGERALD, GA · NPI 1740370691
Verified facts
What the public records show
CMS Open Payments records show Thomas R Mann, M.D.PC received $525.76 in general payments during 2025 across 25 reported records.
GlaxoSmithKline, LLC. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $115.78 | 22.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.76 | 19.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.71 | 17.4% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $57.11 | 10.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.40 | 6.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.33 | 6.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.18 | 4.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.19 | 3.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.95 | 3.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.32 | 2.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.03 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $525.76 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $115.78 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.15 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.19 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $68.43 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $57.11 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.40 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $32.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.08 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.32 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 152 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 89 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
36 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
152 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 503 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 494 | 118 |
| Gabapentin | Gabapentin | 463 | 100 |
| Potassium Chloride | Potassium Chloride | 462 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 393 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 331 | 76 |
| Alprazolam | Alprazolam | 293 | 53 |
| Losartan Potassium | Losartan Potassium | 282 | 73 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 275 | 36 |
| Meloxicam | Meloxicam | 251 | 64 |
| Omeprazole | Omeprazole | 242 | 69 |
| Tramadol Hcl | Tramadol Hcl | 233 | 61 |
| Lisinopril | Lisinopril | 228 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 218 | 51 |
| Metformin Hcl | Metformin Hcl | 198 | 60 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 194 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 35 |
| Montelukast Sodium | Montelukast Sodium | 187 | 36 |
| Bupropion Xl | Bupropion Hcl | 186 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 45 |
| Furosemide | Furosemide | 182 | 36 |
| Carvedilol | Carvedilol | 169 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 169 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 50 |
| Eliquis | Apixaban | 167 | 35 |
| Mounjaro | Tirzepatide | 152 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 42 |
| Glimepiride | Glimepiride | 145 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 145 | 41 |
| Spironolactone | Spironolactone | 134 | 30 |
| Celecoxib | Celecoxib | 133 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 130 | 44 |
| Nifedipine Er | Nifedipine | 130 | 28 |
| Pregabalin | Pregabalin | 126 | 30 |
| Trazodone Hcl | Trazodone Hcl | 120 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 25 |
| Ozempic | Semaglutide | 111 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 39 |
| Jardiance | Empagliflozin | 109 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 101 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 101 | 23 |
| Clonazepam | Clonazepam | 100 | 18 |
| Famotidine | Famotidine | 99 | 28 |
| Metformin Hcl Er | Metformin Hcl | 96 | 20 |
| Simvastatin | Simvastatin | 94 | 21 |
| Sertraline Hcl | Sertraline Hcl | 93 | 22 |
| Allopurinol | Allopurinol | 92 | 18 |
| Lorazepam | Lorazepam | 92 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 16 |
| Torsemide | Torsemide | 86 | 34 |
| Buspirone Hcl | Buspirone Hcl | 85 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 79 | suppressed |
| Chlorthalidone | Chlorthalidone | 77 | 16 |
| Telmisartan | Telmisartan | 77 | 22 |
| Donepezil Hcl | Donepezil Hcl | 75 | 19 |
| Levetiracetam | Levetiracetam | 74 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 18 |
| Prednisone | Prednisone | 67 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 27 |
| Linzess | Linaclotide | 62 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 18 |
| Mirtazapine | Mirtazapine | 61 | 16 |
| Indapamide | Indapamide | 58 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 14 |
| Clonidine Hcl | Clonidine Hcl | 55 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 14 |
| Diazepam | Diazepam | 53 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 53 | 14 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 12 |
| Tradjenta | Linagliptin | 51 | suppressed |
| Belsomra | Suvorexant | 50 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 49 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 49 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 21 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 47 | suppressed |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Nabumetone | Nabumetone | 47 | 14 |
| Alendronate Sodium | Alendronate Sodium | 46 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 46 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | 15 |
| Azithromycin | Azithromycin | 44 | 42 |
| Doxepin Hcl | Doxepin Hcl | 44 | 12 |
| Fentanyl | Fentanyl | 44 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 44 | suppressed |
| Colchicine | Colchicine | 41 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 14 |
| Baclofen | Baclofen | 39 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 38 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 37 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 32 |
| Lubiprostone | Lubiprostone | 35 | 14 |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | 13 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Estradiol | Estradiol | 32 | 14 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Sotalol | Sotalol Hcl | 32 | suppressed |
| Carbamazepine | Carbamazepine | 31 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Glipizide | Glipizide | 28 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 28 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 25 |
| Irbesartan | Irbesartan | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 12 |
| Ondansetron Odt | Ondansetron | 26 | 13 |
| Topiramate | Topiramate | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 20 |
| Mupirocin | Mupirocin | 24 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 17 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Probenecid | Probenecid | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $525.76 · 25 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, FANAPT, IBSRELA, Kerendia, Leqembi, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error